Connections Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).